Which has better earnings & valuation, INAB or DCOY?

IN8bio is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IN8bio N/A N/A -$19.44M -$1.62 N/A Decoy Therapeutics N/A N/A -$12.52M -$106.90 N/A

Is INAB or DCOY more profitable?

IN8bio's return on equity of -91.18% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -91.18% -76.93% Decoy Therapeutics N/A -315.22% -167.15%

Do analysts rate DCOY or GDTC?

Decoy Therapeutics currently has a consensus price target of $30.00, indicating a potential upside of 737.99%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Decoy Therapeutics is more favorable than CytoMed Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 CytoMed Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, DCOY or GDTC?

CytoMed Therapeutics has higher revenue and earnings than Decoy Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Decoy Therapeutics N/A N/A -$12.52M -$106.90 N/A CytoMed Therapeutics $250K 44.90 -$3.10M N/A N/A

Is DCOY or GDTC more profitable?

CytoMed Therapeutics' return on equity of 0.00% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Decoy Therapeutics N/A -315.22% -167.15% CytoMed Therapeutics N/A N/A N/A

Which has better earnings and valuation, AKTX or DCOY?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Akari Therapeutics N/A N/A -$17.30M N/A N/A Decoy Therapeutics N/A N/A -$12.52M -$106.90 N/A

Is AKTX or DCOY more profitable?

Akari Therapeutics' return on equity of -142.03% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Akari Therapeutics N/A -142.03% -73.04% Decoy Therapeutics N/A -315.22% -167.15%

Do analysts rate DCOY or IMRN?

Decoy Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 737.99%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Decoy Therapeutics is more favorable than Immuron. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Immuron 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, DCOY or IMRN?

Immuron has higher revenue and earnings than Decoy Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Decoy Therapeutics N/A N/A -$12.52M -$106.90 N/A Immuron $4.72M 1.88 -$3.38M N/A N/A

Is DCOY or IMRN more profitable?

Immuron's return on equity of 0.00% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Decoy Therapeutics N/A -315.22% -167.15% Immuron N/A N/A N/A

Do analysts rate BCLI or DCOY?

Decoy Therapeutics has a consensus target price of $30.00, indicating a potential upside of 737.99%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Decoy Therapeutics is more favorable than Brainstorm Cell Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, BCLI or DCOY?

Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainstorm Cell Therapeutics N/A N/A -$11.62M -$1.64 N/A Decoy Therapeutics N/A N/A -$12.52M -$106.90 N/A

Is BCLI or DCOY more profitable?

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Decoy Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Brainstorm Cell Therapeutics N/A N/A -519.50% Decoy Therapeutics N/A -315.22% -167.15%

Decoy Therapeutics (DCOY) Competitors

$3.58 +0.05 (+1.42%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$3.62 +0.04 (+1.01%)

As of 08/14/2026 07:55 PM Eastern

Compare

DCOY vs. INAB, GDTC, AKTX, IMRN, and BCLI

Should you buy Decoy Therapeutics stock or one of its competitors? Decoy Therapeutics's main competitors and comparable companies include IN8bio (INAB), CytoMed Therapeutics (GDTC), Akari Therapeutics (AKTX), Immuron (IMRN), and Brainstorm Cell Therapeutics (BCLI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Decoy Therapeutics compare to IN8bio?

IN8bio (NASDAQ:INAB) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation.

IN8bio has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market.

IN8bio is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$1.62	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A

In the previous week, IN8bio had 11 more articles in the media than Decoy Therapeutics. MarketBeat recorded 13 mentions for IN8bio and 2 mentions for Decoy Therapeutics. Decoy Therapeutics' average media sentiment score of 1.47 beat IN8bio's score of 0.78 indicating that Decoy Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
IN8bio	Positive
Decoy Therapeutics	Positive

IN8bio currently has a consensus target price of $4.00, indicating a potential upside of 263.64%. Decoy Therapeutics has a consensus target price of $30.00, indicating a potential upside of 737.99%. Given Decoy Therapeutics' higher possible upside, analysts clearly believe Decoy Therapeutics is more favorable than IN8bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

IN8bio's return on equity of -91.18% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-91.18%	-76.93%
Decoy Therapeutics	N/A	-315.22%	-167.15%

92.1% of IN8bio shares are owned by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are owned by institutional investors. 14.5% of IN8bio shares are owned by company insiders. Comparatively, 1.5% of Decoy Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

IN8bio beats Decoy Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Decoy Therapeutics compare to CytoMed Therapeutics?

Decoy Therapeutics (NASDAQ:DCOY) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, valuation, analyst recommendations, dividends, earnings and profitability.

CytoMed Therapeutics has higher revenue and earnings than Decoy Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A
CytoMed Therapeutics	$250K	44.90	-$3.10M	N/A	N/A

11.9% of Decoy Therapeutics shares are held by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are held by institutional investors. 1.5% of Decoy Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Decoy Therapeutics currently has a consensus price target of $30.00, indicating a potential upside of 737.99%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Decoy Therapeutics is more favorable than CytoMed Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CytoMed Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Decoy Therapeutics has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, CytoMed Therapeutics has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market.

In the previous week, Decoy Therapeutics and Decoy Therapeutics both had 2 articles in the media. Decoy Therapeutics' average media sentiment score of 1.47 beat CytoMed Therapeutics' score of 1.43 indicating that Decoy Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Decoy Therapeutics	Positive
CytoMed Therapeutics	Positive

CytoMed Therapeutics' return on equity of 0.00% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-315.22%	-167.15%
CytoMed Therapeutics	N/A	N/A	N/A

Summary

Decoy Therapeutics beats CytoMed Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Decoy Therapeutics compare to Akari Therapeutics?

Akari Therapeutics (NASDAQ:AKTX) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

In the previous week, Akari Therapeutics had 1 more articles in the media than Decoy Therapeutics. MarketBeat recorded 3 mentions for Akari Therapeutics and 2 mentions for Decoy Therapeutics. Decoy Therapeutics' average media sentiment score of 1.47 beat Akari Therapeutics' score of 0.30 indicating that Decoy Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Akari Therapeutics	Neutral
Decoy Therapeutics	Positive

Akari Therapeutics currently has a consensus target price of $32.33, suggesting a potential upside of 328.82%. Decoy Therapeutics has a consensus target price of $30.00, suggesting a potential upside of 737.99%. Given Decoy Therapeutics' higher possible upside, analysts clearly believe Decoy Therapeutics is more favorable than Akari Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akari Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akari Therapeutics	N/A	N/A	-$17.30M	N/A	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A

5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are owned by institutional investors. 32.2% of Akari Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Decoy Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Akari Therapeutics' return on equity of -142.03% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akari Therapeutics	N/A	-142.03%	-73.04%
Decoy Therapeutics	N/A	-315.22%	-167.15%

Akari Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market.

Summary

Akari Therapeutics beats Decoy Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Decoy Therapeutics compare to Immuron?

Decoy Therapeutics (NASDAQ:DCOY) and Immuron (NASDAQ:IMRN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Immuron has higher revenue and earnings than Decoy Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A
Immuron	$4.72M	1.88	-$3.38M	N/A	N/A

Immuron's return on equity of 0.00% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-315.22%	-167.15%
Immuron	N/A	N/A	N/A

11.9% of Decoy Therapeutics shares are owned by institutional investors. Comparatively, 0.1% of Immuron shares are owned by institutional investors. 1.5% of Decoy Therapeutics shares are owned by company insiders. Comparatively, 7.0% of Immuron shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Decoy Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 737.99%. Given Decoy Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Decoy Therapeutics is more favorable than Immuron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Immuron	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Decoy Therapeutics has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Immuron has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market.

In the previous week, Immuron had 1 more articles in the media than Decoy Therapeutics. MarketBeat recorded 3 mentions for Immuron and 2 mentions for Decoy Therapeutics. Decoy Therapeutics' average media sentiment score of 1.47 beat Immuron's score of 0.96 indicating that Decoy Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Decoy Therapeutics	Positive
Immuron	Positive

Summary

Immuron beats Decoy Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Decoy Therapeutics compare to Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than Decoy Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A
Decoy Therapeutics	N/A	N/A	-$12.52M	-$106.90	N/A

14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are owned by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Decoy Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Brainstorm Cell Therapeutics and Brainstorm Cell Therapeutics both had 2 articles in the media. Decoy Therapeutics' average media sentiment score of 1.47 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Decoy Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Brainstorm Cell Therapeutics	Neutral
Decoy Therapeutics	Positive

Decoy Therapeutics has a consensus target price of $30.00, indicating a potential upside of 737.99%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Decoy Therapeutics is more favorable than Brainstorm Cell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainstorm Cell Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Brainstorm Cell Therapeutics has a beta of 0.23, meaning that its share price is 77% less volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market.

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%
Decoy Therapeutics	N/A	-315.22%	-167.15%

Summary

Decoy Therapeutics beats Brainstorm Cell Therapeutics on 7 of the 12 factors compared between the two stocks.

Get Decoy Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCOY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCOY vs. The Competition

Export

Metric	Decoy Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.11M	$3.72B	$7.03B	$13.07B
Dividend Yield	N/A	3.69%	2.57%	10.65%
P/E Ratio	-0.03	10.77	271.26	25.40
Price / Sales	N/A	1,367.37	623.44	105.59
Price / Cash	N/A	101.42	75.70	53.27
Price / Book	0.49	16.78	12.92	6.21
Net Income	-$12.52M	-$13.32M	$3.45B	$347.71M
7 Day Performance	-8.91%	1.76%	1.16%	1.08%
1 Month Performance	-40.23%	2.86%	2.17%	1.87%
1 Year Performance	N/A	54.10%	62.38%	20.79%

Decoy Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCOY Decoy Therapeutics	2.1894 of 5 stars	$3.58 +1.4%	$30.00 +738.0%	N/A	$2.11M	N/A	N/A	20	Earnings Report Gap Down
INAB IN8bio	3.3327 of 5 stars	$0.98 +0.9%	$4.00 +308.7%	-53.6%	$9.55M	N/A	N/A	20	News Coverage Analyst Revision
GDTC CytoMed Therapeutics	0.9092 of 5 stars	$0.83 +3.6%	N/A	-47.3%	$9.50M	$250K	N/A	N/A	Positive News Short Interest Decrease
AKTX Akari Therapeutics	2.3649 of 5 stars	$7.00 -13.4%	$32.33 +361.9%	-81.3%	$9.25M	N/A	N/A	9	News Coverage Upcoming Earnings Short Interest Increase
IMRN Immuron	0.7748 of 5 stars	$1.07 -3.2%	N/A	-38.9%	$8.88M	$4.72M	N/A	N/A	Short Interest Decrease Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCOY) was last updated on 8/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Decoy Therapeutics (DCOY) Competitors

DCOY vs. INAB, GDTC, AKTX, IMRN, and BCLI

How does Decoy Therapeutics compare to IN8bio?

Summary

How does Decoy Therapeutics compare to CytoMed Therapeutics?

Summary

How does Decoy Therapeutics compare to Akari Therapeutics?

Summary

How does Decoy Therapeutics compare to Immuron?

Summary

How does Decoy Therapeutics compare to Brainstorm Cell Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCOY vs. The Competition

Decoy Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Decoy Therapeutics (DCOY) Competitors

DCOY vs. INAB, GDTC, AKTX, IMRN, and BCLI

How does Decoy Therapeutics compare to IN8bio?

Which has more volatility & risk, INAB or DCOY?

Which has better earnings & valuation, INAB or DCOY?

Does the media prefer INAB or DCOY?

Do analysts recommend INAB or DCOY?

Is INAB or DCOY more profitable?

Do institutionals & insiders believe in INAB or DCOY?

Summary

How does Decoy Therapeutics compare to CytoMed Therapeutics?

Which has preferable earnings & valuation, DCOY or GDTC?

Do insiders & institutionals have more ownership in DCOY or GDTC?

Do analysts rate DCOY or GDTC?

Which has more risk & volatility, DCOY or GDTC?

Does the media favor DCOY or GDTC?

Is DCOY or GDTC more profitable?

Summary

How does Decoy Therapeutics compare to Akari Therapeutics?

Does the media prefer AKTX or DCOY?

Do analysts rate AKTX or DCOY?

Which has better earnings and valuation, AKTX or DCOY?

Do institutionals and insiders have more ownership in AKTX or DCOY?

Is AKTX or DCOY more profitable?

Which has more volatility & risk, AKTX or DCOY?

Summary

How does Decoy Therapeutics compare to Immuron?

Which has stronger earnings & valuation, DCOY or IMRN?

Is DCOY or IMRN more profitable?

Do institutionals & insiders hold more shares of DCOY or IMRN?

Do analysts rate DCOY or IMRN?

Which has more risk and volatility, DCOY or IMRN?

Does the media refer more to DCOY or IMRN?

Summary

How does Decoy Therapeutics compare to Brainstorm Cell Therapeutics?

Which has preferable valuation & earnings, BCLI or DCOY?

Do insiders & institutionals believe in BCLI or DCOY?

Does the media prefer BCLI or DCOY?

Do analysts rate BCLI or DCOY?

Which has more volatility and risk, BCLI or DCOY?

Is BCLI or DCOY more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCOY vs. The Competition

Decoy Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools